With 'The Howling' celebrating its 45th anniversary, we look back at why it has the scariest werewolf transformation scene of ...
Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) yesterday and set a price target of $9.00. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results